T Cell-Based Gene Therapy of Cancer

Gill, Saar; Kalos, Michael

doi:10.1016/b978-0-12-800563-7.00018-x

Cited by 5 publications

(10 citation statements)

References 180 publications

(143 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second generation CARs, where costimulatory molecules are included in trans , have also been developed, enabling the ability to more precisely potentially modulate CAR functionality . Most current clinical trials evaluate second generation CAR designs .…”

Section: Immune Effector Cells In Actmentioning

confidence: 99%

Adoptive immunotherapy for cancer

Ruella

Kalos

2013

Immunological Reviews

Self Cite

126

View full text Add to dashboard Cite

Recent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T-lymphocyte-based adoptive cell therapy to treat a broad range of malignancies. In this review, we summarize concepts, successes, and challenges for the broader development of this promising field, focusing principally on lessons gleaned from immunological principles and clinical thought. We present ACT in the context of integrating T-cell and tumor biology and the broader systemic immune response.

show abstract

Section: Immune Effector Cells In Actmentioning

confidence: 99%

Adoptive immunotherapy for cancer

Ruella

Kalos

2013

Immunological Reviews

Self Cite

126

View full text Add to dashboard Cite

show abstract

“…Introduction of cysteine residue technology allowed for transferred a and b chains to pair appropriately. 80 Which Antigen?…”

Section: High Affinity Tcrsmentioning

confidence: 99%

“…79 Retroviral or lentiviral transduction strategies are applied to introduce TCR genes into the T cell. 80 Early technical problems for TCR based therapies were low levels of expression of transferred TCR at the cell surface and mispairings of host a and transferred b chains (or vice versa). 81 Recent advances in TCR engineering resolved these difficulties.…”

Section: High Affinity Tcrsmentioning

confidence: 99%

“…98 Insertion into third generation of chimeric antigen receptor constructs has been achieved and clinical trials that employ this technology have positive results and show enhanced T cell persistence and function. 80 Technologies that have been developed to deliver high affinity TCR genes to T cells will be effective to modulate enhanced co-stimulatory molecule expression as well.…”

Section: Tumor Tolerance Of Tcrsmentioning

confidence: 99%

See 1 more Smart Citation

To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy

Thaxton

2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

T cell adoptive therapies for immune-mediated regression of cancers have attracted a great deal of recent attention. Clinical results are glamorous, yet much remains to be uncovered behind the basic science that allows us to engineer T cells and T cell receptors (TCRs) for clinical use. We discuss the development of TCRs for therapeutic use in the context of thymic selection toward central tolerance and we review therapies based on tumor infiltrating lymphocytes (TILs), endogenous antigen specific TCRs, and engineered TCRs. Further we discuss the development of low and high affinity TCRs and the extent to which each challenges central tolerance. Current results suggest that adaptation of TCR engineering of moderate affinity TCRs coupled with coregulatory and stimulatory molecules may be the safest and most efficacious road for TCR development aimed at tumor abolition.

show abstract

“…Strategies adopted for cancer immunotherapy is diverse, including but not limited to the use of monoclonal antibodies (mAb), chimeric antigen receptor T cells (CAR T-cells) and other adoptive T-cell therapies and gene therapies, cytokines and cancer vaccines including DNA vaccines. 8,9 One of the cancers that pharmaceutical advances have not made a lot of progress in overall survival is ovarian cancer. There is an urgent need for innovative new approaches in ovarian cancer; one of which can be utilizing pharmaceutical biotechnological methods for immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

Complement system's role in cancer and its therapeutic potential in ovarian cancer

Bareke

Akbuğa

2018

Scand J Immunol

View full text Add to dashboard Cite

Cancer immunotherapy is a strong candidate for the long-awaited new edition to standard cancer therapies. For an effective immunotherapy, it is imperative to delineate the players of antitumour immune response. As an important innate immune system effector mechanism, complement is highly likely to play a substantial role in cancer immunity. Studies suggest that there may be two different "states of complement" that show opposing effects on cancer cells; a complement profile that has antitumour effects with low expression of membrane-bound complement regulator proteins (mCRPs), lytic membrane attack complex (MAC) concentration and moderate C5a concentration, and a complement profile that has protumour effects with high expression of mCRPs, sublytic MAC and high concentrations of C5a. One of the cancers that urgently require innovative therapeutic approaches is ovarian cancer, and complement has a potential to be a good target for this purpose. A combinatorial approach where the complement cascade is fine-tuned by inhibiting some of its activities while promoting the others can prove to be a fruitful approach. Herein, we will briefly discuss the cancer-immune system interaction and then present a discussion of complement system's role in tumour immunity and its therapeutic potential for ovarian cancer immunotherapy.

show abstract

T Cell-Based Gene Therapy of Cancer

Cited by 5 publications

References 180 publications

Adoptive immunotherapy for cancer

Adoptive immunotherapy for cancer

To affinity and beyond: Harnessing the T Cell receptor for cancer immunotherapy

Complement system's role in cancer and its therapeutic potential in ovarian cancer

Contact Info

Product

Resources

About